OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Stock
Fundamentals
Technical indicators
- RSI 14
- 26.29
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.27
- MACD histogram
- -0.01
- SMA 50
- $3.49
- Price below SMA 50
- EMA 50
- $3.34
- Price below EMA 50
- SMA 200
- $3.66
- Price below SMA 200
- EMA 200
- $3.49
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
About OnKure Therapeutics, Inc. Class A Common Stock
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director | 1959 |
| Mr. Jason A. Leverone CPA | Chief Financial Officer | 1974 |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 1973 |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary | — |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery | — |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology | — |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry | — |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 26.29
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.27
- MACD histogram
- -0.01
- SMA 50
- $3.49
- Price below SMA 50
- EMA 50
- $3.34
- Price below EMA 50
- SMA 200
- $3.66
- Price below SMA 200
- EMA 200
- $3.49
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $17.50
- High
- $21.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.6 | -14.3 | -9.7 | -23.3 | +3.5 |




